New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy
作者： Mizuki Nishino , David M. Jackman , Hiroto Hatabu , Beow Y. Yeap , Leigh-Anne Cioffredi
DOI: 10.2214/AJR.09.3928
关键词: PET-CT 、 Clinical trial 、 Erlotinib Hydrochloride 、 Lung cancer 、 Erlotinib 、 Guideline 、 Targeted therapy 、 Radiology 、 Medicine 、 Response Evaluation Criteria in Solid Tumors
摘要: OBJECTIVE. The purpose of this article is to compare the recently published revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1) original (RECIST 1.0) for advanced non–small cell lung cancer (NSCLC) after erlotinib therapy and evaluate impact new CT tumor measurement guideline on response assessment.MATERIALS AND METHODS. Forty-three chemotherapy-naive patients with NSCLC treated a single-arm phase 2 multicenter open-label clinical trial were retrospectively studied. records using RECIST 1.0 that generated as part prospective reviewed. A second set measurements was from meet 1.1 guidelines. number target lesions, best response, time progression compared between 1.0.RESULTS. lesions according decreased 22 (51%) did not change ...
sci-hub.se 参考文章(20)
Jan Bogaerts, Robert Ford, Dan Sargent, Lawrence H. Schwartz, Larry Rubinstein, Denis Lacombe, Elizabeth Eisenhauer, Jaap Verweij, Patrick Therasse, Individual patient data analysis to assess modifications to the RECIST criteria. European Journal of Cancer. ,vol. 45, pp. 248- 260 ,(2009) , 10.1016/J.EJCA.2008.10.027
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073
J. Martin Bland, Douglas G. Altman, Statistical methods for assessing agreement between two methods of clinical measurement International Journal of Nursing Studies. ,vol. 47, pp. 931- 936 ,(2010) , 10.1016/J.IJNURSTU.2009.10.001
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238
J. Martin Bland, DouglasG. Altman, Statistical methods for assessing agreement between two methods of clinical measurement. The Lancet. ,vol. 327, pp. 307- 310 ,(1986) , 10.1016/S0140-6736(86)90837-8
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026
A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, M. J. Thun, Cancer statistics, 2008. CA: A Cancer Journal for Clinicians. ,vol. 58, pp. 71- 96 ,(2008) , 10.3322/CA.2007.0010
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938